1. Introduction {#sec1-ijms-18-01963}
===============

Proteins are one of the most vital classes of molecules in the cell, carrying out myriad functions that range from enzymatic reactions to cell signaling. Precise functioning and durability of cellular proteins are maintained by the proteostasis network (PN), which governs the biosynthesis, folding and refolding, trafficking, aggregation, and degradation of proteins \[[@B1-ijms-18-01963]\]. This network responds to intracellular alterations or the external microenvironment to sustain protein quality control and cellular functions under both normal and stressful conditions.

The PN comprises approximately over a thousand different factors that function both at an intracellular level and in a coordinated cell-nonautonomous manner \[[@B2-ijms-18-01963]\]. The major categorical players in the PN, which directly and robustly affect the state of the proteome, are protein translational and post-translational machinery, trafficking machinery, molecular chaperones and the heat shock response (HSR), unfolded protein response (UPR), oxidative stress response (OxR), macroautophagy, and the ubiquitin-proteasome system (UPS). The auxiliary players, which exert major influence on these central processes, include cell signaling pathways, epigenetic modifiers, aging and metabolic factors \[[@B3-ijms-18-01963],[@B4-ijms-18-01963]\]. These major and auxiliary players combine in each individual cell type to address the needs of the cell and tailor a cell-type specific PN. Because neurons exhibit unique morphology, lifespan and functional complexity, these cells rely heavily on the PN to operate seamlessly and provide an uninterrupted, robust network of functional protein units. Therefore, the involvement of each categorical player in the PN is currently under intense investigation in the context of toxic gain-of-function neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) \[[@B5-ijms-18-01963]\].

Several major cell signaling pathways could influence the central pathways of PN. For example, the MAPK pathway has been implicated in governing protein aggregation, HSR, ER stress, and other stress-mediated responses in neuronal cells \[[@B6-ijms-18-01963],[@B7-ijms-18-01963],[@B8-ijms-18-01963]\]. It is increasingly evident that post-translational modifications of cell signaling proteins represents a major control mechanism for proteostasis \[[@B9-ijms-18-01963]\]. For example, Phosphorylation is one such modification, where the addition of one or more phosphate moieties is carried out by protein kinases and removal of phosphates is performed by protein phosphatases. Intriguingly, protein phosphatases comprise just 0.84% of the human proteome whereas protein kinases make up 2.39% \[[@B10-ijms-18-01963]\], which may insinuate multiple downstream dephosphorylation targets for an individual phosphatase. The importance of balanced protein phosphorylation and dephosphorylation can be attested by the devastating effects of protein phosphorylation in stabilizing certain neurotoxic aggregates. Conversely, different phosphorylation events may ameliorate certain types of neurotoxicity \[[@B11-ijms-18-01963]\], and dephosphorylation may be undesirable. Moreover, the interaction between PN and the physiological state of a certain protein assembly, is referred to as the quinary state of that protein \[[@B4-ijms-18-01963]\]. It has been postulated that phosphorylation could influence this quinary state potentially by altering charge-charge interactions between interacting partners \[[@B12-ijms-18-01963]\]. It provides another possible means by which phosphorylation, and further, dephosphorylation could influence proteostasis.

Dual-specificity phosphatases (DUSPs) are Class I classical cysteine-based protein phosphatases that have the dual ability to dephosphorylate phospho-serine/threonine and phospho-tyrosine residues. The first evidence of dual-specific phosphatase activity was reported by Guan et al. in 1991 for vaccinia virus VH1 phosphatase. There are now 44 different human DUSPs that have been identified and grouped into six subfamilies: (i) Mitogen-activated Protein Kinase Phosphatases (MKPs); (ii) Atypical DUSPs; (iii) Slingshot Protein Phosphatases; (iv) Protein Tyrosine Phosphatases type IVA; (v) CDC14 Phosphatases and (vi) PTEN Protein Phosphatases, as listed by the HUGO Gene Nomenclature Committee. [Figure 1](#ijms-18-01963-f001){ref-type="fig"} illustrates the sub-classifications for the different members of the DUSP family, whereas [Figure 2](#ijms-18-01963-f002){ref-type="fig"} delineates the structural features of representative members from each DUSP subfamily. The alternative names of the DUSP members are listed in [Appendix A](#app1-ijms-18-01963){ref-type="app"}. The classical DUSPs, or MKPs, are involved in dephosphorylating mitogen or stress-activated ERK, JNK and p38 kinases. The substrates of atypical DUSPs are varied, and include: ERK, JNK, p38, STAT, AKT, and PI(5)P. Some targets of CDC14 family include proteins like ERK3, p53, RN-tre, CDK2, PLK1, while those of PTP14 family includes ezrin, EF-2, ATF-7, p53, and KIT. Substrates of Slingshot protein phosphatases include ADF, cofilin and LIMK1 (HGNC), and those of the PTEN protein phosphatase family include PIP3, PP1α, and AKT \[[@B13-ijms-18-01963],[@B14-ijms-18-01963],[@B15-ijms-18-01963],[@B16-ijms-18-01963],[@B17-ijms-18-01963]\]. From the above examples, it is clear that DUSPs regulate various essential cell signaling pathways. Furthermore, the importance of DUSPs is rapidly gaining ground based on studies in neurodegenerative disease models. For example, DUSP26 has been shown to stimulate Aβ production during hypoxia, while DUSP1 expression is upregulated in PD, and was shown to be neuroprotective against mutant Huntingtin \[[@B6-ijms-18-01963],[@B18-ijms-18-01963],[@B19-ijms-18-01963]\]. DUSPs may therefore be considered as candidate therapeutic targets with the potential for manipulating disease microenvironments.

The question then arises---how do DUSPs influence proteostasis? In this review, we will discuss existing evidence that DUSPs function to surveil the PN, primarily, by regulating cell signaling and thereby affecting a few of the central PN pathways. We will then provide a unifying model on how DUSPs regulate these central pathways which come together during neuronal proteostasis. Lastly, we will offer perspectives on modulating DUSPs for therapeutic application.

2. Mechanisms by Which DUSPs May Affect Neuronal Proteostasis {#sec2-ijms-18-01963}
=============================================================

DUSPs bear a conserved catalytic motif H-C-X-X-X-X-X-R-(S/T), where X could be any amino acid. While this class of molecules regulates many proteins by serine/threonine and tyrosine dephosphorylation, DUSPs are themselves regulated by transcription, post-translational modifications and catalytic modulation \[[@B71-ijms-18-01963]\]. Intriguingly, several DUSPs have been linked to various neurological disorders, including several neurodegenerative diseases, as indicated in [Table 1](#ijms-18-01963-t001){ref-type="table"}. Some DUSPs which do not have a clear role in neurological diseases have otherwise been associated with neuron or oligodendrocyte development, and thus may potentially play as yet unidentified roles in neuronal dysfunction. Additionally, two DUSPs have appeared in genome-wide association studies (GWAS) of neuronal disorders and await further confirmation, and only a few remain unassociated with neurological diseases. Here, we will overview some means by which DUSPs may participate in neuronal proteostasis.

2.1. DUSPs Act through Mitogen-Activated and Stress-Activated Protein Kinases {#sec2dot1-ijms-18-01963}
-----------------------------------------------------------------------------

Mitogen- and stress-activated protein kinases (MAPK/SAPKs; hereafter referred as MAPKs) are one of the chief cell signaling pathways that phosphorylate proteins on Ser/Thr/Tyr residues to induce responses in a cascade of downstream effectors. The MAPKs are involved in cell signaling, cell cycle, chromatin remodeling, cell fate determination, neuronal plasticity, learning and memory, and apoptosis \[[@B72-ijms-18-01963],[@B73-ijms-18-01963]\]. In particular, the extracellular signal-regulated kinases (ERK) have been implicated in oxidative stress, stroke, seizure, Lewy body immunoreactivity, tau phosphorylation, and excitoxicity \[[@B74-ijms-18-01963],[@B75-ijms-18-01963]\]. Similarly, the c-Jun N-terminal kinase (JNK) signaling is involved in tau-induced neurotoxicity, modulating amyloid-β levels, excitotoxicity, ischemia, neuroinflammation, and oxidative stress \[[@B76-ijms-18-01963]\]. The p38 signaling pathway regulates tau phosphorylation, inflammatory response, focal cerebral ischemia, excitoxicity, α-synuclein mediated activation, and colocalization with amyloid-β \[[@B77-ijms-18-01963]\]. Moreover, MAPKs often regulate the transcription of downstream *DUSP* genes, thereby creating a negative feedback loop \[[@B78-ijms-18-01963]\].

MKPs interact with MAPKs via several sites in addition to the MAPK-binding domain that defines the subfamily. This complex interaction may allow some DUSPs to exhibit preferential dephosphorylation of certain MAPKs compared to others. For example, DUSP1 more readily dephosphorylates JNK and p38, than ERK. The differences in substrate specificity among classical DUSPs/MKPs are attributed to various interaction sites, particularly, in the Rhodanese (containing MAPK-binding sites) and catalytic domains \[[@B13-ijms-18-01963]\]. The atypical DUSPs, on the other hand, have varied dephosphorylation substrates which also include the MAPKs, despite the lack of a specific MAPK binding motif in atypical DUSPs \[[@B13-ijms-18-01963]\]. There is no information currently available on whether DUSP subfamilies other than MKPs and atypical DUSPs can dephosphorylate MAPKs. However, like atypical DUSPs, the other subfamilies lack a defined MAPK-binding domain \[[@B27-ijms-18-01963]\], ([Table 1](#ijms-18-01963-t001){ref-type="table"}), suggesting that the interactions may be variable between individual proteins.

2.2. DUSPs Act through Other Mechanisms Based on Their Unique Functional Domains {#sec2dot2-ijms-18-01963}
--------------------------------------------------------------------------------

All DUSP subfamilies have unique features in substrate docking motifs, conformation or specific domains which can recognize different substrates. Some examples of these unique features include slingshot phosphatase domains of the Slingshot subfamily, tensin-type phosphatase domain of the PTEN subfamily, a Pro residue in the active site of CDC14B, and shallow active site cleft and hydrophobic residues in the signature motif of the PTP4A subfamily. On the basis of these and other unique features, various DUSPs are capable of functioning as mRNA-capping enzymes, scaffolding phosphatases and scaffolding pseudophosphatases, mitochondrial phosphatases, or dual-specificity protein-and-glucan phosphatases. A concise description of the various domains in different DUSP family members is provided in [Table 1](#ijms-18-01963-t001){ref-type="table"}, and excellent, detailed reviews on the various domains and features of DUSPs have been published previously \[[@B14-ijms-18-01963],[@B71-ijms-18-01963]\]. Evidence for these alternative mechanisms in regulation of neuronal proteostasis are not aplenty, leaving a wide scope for potential future investigations.

3. DUSPs in Protein Aggregation Diseases {#sec3-ijms-18-01963}
========================================

The relevance of protein phosphorylation as a modifier of proteostasis in certain aggregation-prone neuronal proteins has been previously described. For example, hyperphosphorylation of the neuronal tau protein at Ser199, Ser202, and Thr205 is recognized as a key event that leads to the formation of neurofibrillary tangles and synaptic loss in various tauopathies \[[@B11-ijms-18-01963]\]. Evidence also point to the involvement of α-synuclein phosphorylation at sites Ser87, Ser129, Tyr125, Tyr133, and Tyr136 in PD etiology. Phosphorylation of amyloid-β at Ser26 leads to its stabilization and subsequent increase in its neurotoxicity, and moreover, phosphorylation of TDP-43 at Ser379, Ser403, Ser404, Ser409, and Ser410 also boosts aggregate formation \[[@B79-ijms-18-01963],[@B80-ijms-18-01963]\].

On the other hand, phosphorylation of certain proteins or blocking certain phosphatases can also be helpful for maintaining neuronal health. For example, phosphatases, PP2B and STEP, have been implicated in promoting the pathogenesis of AD \[[@B81-ijms-18-01963]\]. Furthermore, some reports suggest that eIF2α dephosphorylation is important in proteinopathies \[[@B82-ijms-18-01963]\]. Several reports have indicated that some phosphorylation events may decrease the levels of toxic protein assemblies and even promote their degradation \[[@B11-ijms-18-01963],[@B80-ijms-18-01963]\]. Perhaps the strongest example for the beneficial effects of phosphorylation has been reported for huntingtin, whose phosphorylation at Ser13, Ser16, or Ser421 could promote its clearance by the ubiquitin-proteasome system \[[@B80-ijms-18-01963]\]. Furthermore, phosphorylation at Thr3 of huntingtin can reduce neurotoxicity by forming microscopic aggregates that offset HD pathogenesis \[[@B80-ijms-18-01963]\]. Whether the effects of phosphorylation are protective or toxic, all of these examples nevertheless underscore the crucial impact of dephosphorylation as the diametrically opposite regulatory process. It is interesting to note that phosphorylation occurs at Ser residues 95% of the time, followed by Thr (4%) and Tyr (1%) \[[@B10-ijms-18-01963]\], thus placing dual-specificity phosphatases at an advantage among other dephosphorylating moieties. In this section, we will define the possible means by which DUSPs could participate in the protein aggregation response.

Several DUSPs can regulate MAPKs or related proteins through dephosphorylation. For example, DUSP1 has been shown to dephosphorylate JNK and p38 kinases in an HD model and its expression is increased in the 6-hydroxydopamine (6-OHDA) rat model of PD, suggesting that DUSP may be neuroprotective in both diseases \[[@B19-ijms-18-01963]\]. BDNF-induced DUSP1 can dephosphorylate JNK and affect axonal branching \[[@B83-ijms-18-01963]\]. The levels of both DUSP1 and DUSP6 are decreased in cases of familial amyloidotic polyneuropathy, and the levels of phospho-ERK are elevated leading to subsequent cytotoxicity \[[@B84-ijms-18-01963]\]. DUSP6 knockdown can increase the level of phospho-ERK to promote high levels of tau phosphorylation. Interestingly, the protein level of DUSP6 was found to be decreased in AD brain lysates \[[@B85-ijms-18-01963]\]. DUSP26 has been shown to regulate amyloid-precursor protein (APP) for amyloid-β production by inducing JNK phosphorylation \[[@B6-ijms-18-01963]\]. Additionally, DUSP16 can dephosphorylate JNK3 that is bound to β-arrestin 2 in COS-7 cells, which may also occur in neurons \[[@B86-ijms-18-01963],[@B87-ijms-18-01963]\]. Although no significant upregulation of JNK phosphorylation was observed in sensory (dorsal root ganglia) neurons isolated from *DUSP16* knock-out mice, we suppose the discrepancy could be due to the different systems used in each study and also the absence of JNK activator, ASK1, in the knock-out mouse model \[[@B39-ijms-18-01963]\].

Apart from MAPKs, there are various other signaling targets that are modulated by DUSPs. p53 is associated with neurodegenerative diseases like AD, PD, and HD, where it participates in processes that regulate or respond to apoptosis, mitochondrial dysfunction, neuronal injury and possibly, protein misfolding \[[@B88-ijms-18-01963]\]. The *DUSP16* knock-out has been shown to enhance phosphorylation of p53 at Ser15 in sensory neurons upon trophic factor withdrawal \[[@B39-ijms-18-01963]\]. Analogously, DUSP26 can also dephosphorylate p53 at Ser20 and Ser37, thus suggesting a role for DUSPs in regulating p53-mediated pathways \[[@B89-ijms-18-01963]\]. DUSP22 has been shown to be induced by the pro-inflammatory cytokine interleukin-6 (IL-6) and could dephosphorylate STAT3 in hepatoma cells, creating a feedback loop for the IL-6/STAT3 signaling \[[@B90-ijms-18-01963]\]. Curiously enough, IL-6 can prompt several downstream responses such as upregulation of cdk5/p53 complex and phosphorylation of STAT3 and ERK, all of which integrate to hyperphosphorylate tau protein \[[@B90-ijms-18-01963]\]. Whether DUSP22-mediated regulation of IL-6 has any implications in tauopathies may be an interesting topic for study, since it has already been shown that DUSP22 can influence tau phosphorylation via a protein kinase A-dependent pathway \[[@B49-ijms-18-01963]\].

Actin depolymerizing factor (ADF)/cofilin are actin binding proteins which regulate the dynamics of actin polymerization during axonal transport and neurodevelopment \[[@B91-ijms-18-01963]\]. Slingshot phosphatases can dephosphorylate and thus activate cofilin. Under stressful conditions, activated cofilin has a propensity to aggregate with ADP-actin, forming cofilin rods that hinder vesicular transportation and promote neurite atrophy. Consequently, cofilin rods have been associated with glutamate excitoxicity, oxidative stress, amyloid-β, neuropil threads, huntingtin, and ischemia \[[@B92-ijms-18-01963]\]. Blocking slingshot-mediated dephosphorylation can at least partially prevent induction of cofilin rods \[[@B93-ijms-18-01963]\]. Recently, it was demonstrated that cofilin can associate with the cellular form of prion protein (PrP^C^) in sporadic Creutzfeldt-Jakob disease subtypes and higher levels of SSH1 could be detected in disease samples. This study creditably underscores the cofilin-SSH1 interaction as a contributor of neurodegeneration \[[@B94-ijms-18-01963]\]. Further, PTEN is a lipid and protein phosphatase that inhibits PI3/AKT signaling and inhibiting PTEN has neuroprotective effects in an AD mouse model, amyloid-β toxicity, a PD model, and lab models of spinal muscular atrophy \[[@B95-ijms-18-01963]\]. PTEN inhibition has also been shown to reduce apoptosis and counteract ER-stress related proteins in an AD mouse model \[[@B96-ijms-18-01963]\]. In contrast, however, PTEN overexpression seems to be neuroprotective in tauopathies \[[@B97-ijms-18-01963]\]. In conclusion, DUSPs should be easily recognized as critical regulators of protein aggregation, which occurs mainly by manipulating phosphorylated proteins.

4. DUSPs in the Heat Shock Response Pathway {#sec4-ijms-18-01963}
===========================================

The heat shock response (HSR) is a conserved proteostasis pathway that restores proper conformation of proteins which become unfolded or aggregated under physiological or stressful conditions. The general mechanism of the HSR involves (a) induction of various signaling cascades in response to stress; (b) activation of the heat shock transcription factors (HSFs), such as the activation of HSF1 by dissociation with its binding partner Hsp90; (c) transcriptional activation of various heat shock proteins (Hsps) by HSFs and (d) refolding of proteins or ubiquitination for degradation \[[@B98-ijms-18-01963]\]. Different kinds of stresses including exposure to high temperatures, heavy metals, or oxidative stress can induce the expression of similar sets of Hsps. There are various classes of heat shock proteins, however, the molecular chaperones are particularly important in neuroprotection and include such proteins as Hsp40, Hsp60, Hsp70, Hsp90, Hsp100 and small Hsp families \[[@B99-ijms-18-01963],[@B100-ijms-18-01963]\]. The involvement of HSR in neurodegenerative diseases may be illustrated by several examples---for one, Hsp70 promotes a decrease in α-synuclein levels in dopaminergic neurons. Additionally, expression of Hsp70, Hsp60 and Hsp40 protects against amyloid-β induced toxicity. Furthermore, Hsp27 protects against superoxide dismustase-1 induced toxicity in an amyotrophic lateral sclerosis (ALS) disease model \[[@B101-ijms-18-01963]\]. Besides the involvement of Hsps in neuroprotection, all three previously mentioned MAPK pathways---ERK, JNK, and p38---are also induced in response to HSR-inducing stressors \[[@B7-ijms-18-01963]\].

From previous works, we may see that several DUSPs are modulated in response to heat shock, and some may also interact directly with Hsps. Although this may not have been necessarily shown in neuronal systems, the HSR pathway is a highly conserved one, and we suspect that some of the mechanistic associations between DUSPs and HSR signaling might also exist in neurons. For instance in Cos-7 cells, the stress-inducible Hsp72 could prevent heat shock-mediated aggregation of DUSP1 and DUSP6, inhibit the activation of ERK signaling, and as a possible consequence, may decrease the survival of stress-damaged cells \[[@B102-ijms-18-01963]\]. The expression of these DUSPs and stress-inducible Hsp72 in neuronal cells suggest that this mechanism may also be at play in neurodegeneration. However, it should be noted that Hsp72 is endogenously expressed only in certain neuronal cell lines \[[@B103-ijms-18-01963]\]. Furthermore, the mouse ortholog of DUSP8 (M3/6) is susceptible to heat shock and tends to aggregate as well, stimulating a concomitant rise in phospho-JNK levels \[[@B104-ijms-18-01963]\]. Polyglutamine stress can also elicit a similar response, though appropriately, Hsp70 expression restricts M3/6 aggregation as well as JNK activation in this model \[[@B105-ijms-18-01963]\].

Stress-mediated ERK activation can induce Hsp70 in neuronal cells. Upon persistent ERK activation, vaccinia-related kinase 3 (VRK3) promotes nuclear localization of Hsp70, which then interacts with DUSP3 to suppress elevated ERK activation. This suggests a route by which dephosphorylation may suppress detrimental ERK levels in neuronal cells \[[@B106-ijms-18-01963]\]. Another phosphatase, DUSP26, can interact with and dephosphorylate the phospho-ERK-activated heat shock transcription factor Hsf4b \[[@B107-ijms-18-01963]\]. Again, all these proteins are expressed in brain regions and have been shown to interact similarly. In non-neuronal cells, it was found that DUSP12 interacts with Hsp70, accumulates in perinuclear region, and protects the cells in response to heat shock \[[@B108-ijms-18-01963]\]. Whether this can hold true in neurons remains to be seen. In contrast, Cdc14 dephosphorylates yeast Hsp90 on a residue that is conserved in the human isoform, but whether this action may occur in neurons is undetermined \[[@B109-ijms-18-01963]\]. Hsp90 inhibition is known to be beneficial for cell survival, although not on a long-term basis. Additionally, it is known that DUSP5 and SSH-1 are likewise susceptible to heat shock as they become inactivated, but whether this is also true in neurons is yet again undetermined \[[@B110-ijms-18-01963],[@B111-ijms-18-01963]\]. In the above examples, we observe a pattern where DUSPs and their dephosphorylation substrates are affected in response to heat shock, and thus may affect the proteostasis signaling repertoire of the afflicted cells. However, modulation of the remaining DUSPs in the context of HSR remains to be probed.

5. DUSPs in Oxidative Stress Response {#sec5-ijms-18-01963}
=====================================

Another distinct pathway acts to combat oxidative stress in the cell. Oxidative stress is essentially the disruption of harmony between reactive oxygen species (ROS) and antioxidant mechanisms. Examples of ROS in the cellular environment include free radicals such as hydroxyl species (OH), superoxide anion (O~2~^−^), and peroxynitrite (ONOO^−^) \[[@B112-ijms-18-01963]\]. Neurodegenerative diseases like AD, PD, and HD include a component of oxidative stress that may be derived from excess ROS production, loss of antioxidant defenses, toxic protein aggregate accumulation, inflammation, mitochondrial dysfunction, or other sources \[[@B113-ijms-18-01963]\]. In general, the protein tyrosine phosphatases are susceptible to oxidative stress at the catalytic cysteine residue, but the presence of an additional Cys residue near the active site of certain DUSPs renders them comparatively less prone to oxidative damage by forming a disulfide bond with the catalytic cysteine. In evidence of this, DUSP4, DUSP13b isoform, DUSP16, and DUSP28 were shown to be capable of recovering more than 70% of their activity after oxidation in one particular study \[[@B114-ijms-18-01963]\]. Since most DUSPs are expected to recover their activity in oxidative conditions, in this segment we will describe how DUSPs may coordinate with the various modulators of oxidative stress response (OxR) to play a role in this aspect of proteostasis.

ERKs are phosphorylated in a cell-type specific manner during oxidative stress, and increased expression is often observed in brain regions that ultimately undergo cell death. DUSPs are important negative regulators of ERK phosphorylation, which is under strict spatiotemporal control by multiple factors, and conversely, ERKs can phosphorylate, and hence activate, downstream DUSPs to generate a negative feedback loop. Thus, it may be suggested that DUSPs may exhibit a critical neuroprotective role of dephosphorylating ERK during conditions of elevated oxidative stress \[[@B115-ijms-18-01963],[@B116-ijms-18-01963]\]. Further, DUSP1 induction was observed in a neuroblastoma cell line under conditions of hypoxia/reoxygenation, and this induction was involved in the downregulation of pro-apoptotic genes and neuronal death \[[@B117-ijms-18-01963]\]. In addition, ROS-induced DNA damage is sensed by PARP-1 whose activity is known to be increased in neurodegenerative diseases like AD and PD. PARP-1 inhibition can exert therapeutic effects partly by increasing DUSP-1 levels, which is followed by reduction in JNK and p38 phosphorylation, as seen in non-neuronal cells \[[@B118-ijms-18-01963],[@B119-ijms-18-01963]\]. Whether the same results can be repeated in neurons remains to be seen. Another interesting example is that of M3/6, which changes its substrate preference from JNK1β and JNK2α to JNK1α and JNK3 isoforms after arsenite-induced oxidative stress. This shift in substrate preference could then affect isoform-specific downstream signaling modules, an observation that is also yet to be replicated in neurons \[[@B120-ijms-18-01963]\].

Furthermore, atypical DUSP PTPMT1 is induced in response to hypoxia by hypoxia-inducible factor HIF-2α in erythroid leukemia cells, and its inhibition induces apoptosis \[[@B121-ijms-18-01963]\]. Whether HIF proteins induce PTPMT1 in non-cancerous neurons under hypoxic conditions is yet another open question, especially since *PTPMT1* single-nucleotide polymorphisms are possibly associated with AD \[[@B122-ijms-18-01963]\]. In one study, inhibition of PTEN was shown to protect neuroblastoma cells against toxicity, oxidative stress, and apoptosis induced by amyloid-β~25--35~ \[[@B123-ijms-18-01963]\]. Oxidative stress can also lead to inhibition of PTP4A1 phosphatase activity in photoreceptor cell models indicating a potential role in stress management \[[@B124-ijms-18-01963]\]. One of the *Drosophila* DUSPs, Puckered, was phosphorylated upon induction of oxidative stress and then dephosphorylated stress-induced JNK \[[@B125-ijms-18-01963]\]. On the other hand, slingshot phosphatase, SSH1, was activated by ROS formation and it in turn activated the cofilin proteins, leading to the formation of cofilin rods which are responsible for neurite atrophy \[[@B126-ijms-18-01963]\]. The involvement of DUSPs during oxidative stress response in neurons is clearly important, and hence, investigation of potential roles for DUSPs in regulating oxidative stress response can offer new avenues for the development of novel therapeutics.

6. DUSPs in Endoplasmic Reticulum Stress, Autophagy and Apoptosis {#sec6-ijms-18-01963}
=================================================================

6.1. Endoplasmic Reticulum Stress {#sec6dot1-ijms-18-01963}
---------------------------------

The endoplasmic reticulum (ER) governs synthesis, folding, and transportation of proteins in a cell. Environmental or physiological stressors such as viruses or gene mutations that cause protein misfolding can overwhelm the quality control systems in the ER, and trigger the ER stress response. An adaptive ER stress response, called the unfolded protein response (UPR), resolves imbalances in protein folding and maturation, accumulation of misfolded proteins or blockades in protein trafficking. The UPR includes PERK, IRE-1α and ATF-6 signaling pathways which induce responses like translation inhibition, antioxidant defenses, ER-associated protein degradation (ERAD), and autophagy. When the UPR can no longer manage ER stress due to accumulation of misfolded proteins or overexposure to other stressors, the distressed cell may commit to programmed cell death (apoptosis), in order to minimize adverse effects on the tissue. Apoptosis induction after ER stress relies on CHOP, IP3R, RYR, JNK, and ASK1 signaling pathways to activate proapoptotic proteins and eventually caspase cleavage \[[@B127-ijms-18-01963],[@B128-ijms-18-01963]\].

Based on previous literature, it is known that the MAPKs act in concert with the ER stress response. ERK signaling may promote cell survival upon the induction of ER stress, possibly, by activating anti-apoptotic factors like BCL-2 and BCL-XL and deactivating pro-apoptotic factors like BIM and PUMA. At least some studies suggest that IRE-1α may activate ERK signaling under stressful conditions, and both IRE-1α and CHOP are known to activate JNK signaling. The JNK pathway is involved in the upregulation pro-apoptotic factors like phosphorylated BIM and BCL2. Another effect of JNK signaling may be to promote cell survival by phosphorylating BCL2, stimulating its dissociation from Beclin1, and thus leading to the induction of autophagy. p38 also acts as a pro-apoptotic signaling molecule under stressful conditions. This kinase can promote cell cycle arrest by activating MK-2, and cell death by phosphorylating proteins like BIM and p53. Moreover, it can also activate ATF6 and CHOP signaling \[[@B8-ijms-18-01963]\]. Hence, depending on the set of substrates that are phosphorylated by different MAPK proteins, different responses may be evoked within the context of ER stress signaling. Therefore, DUSPs that deactivate MAPK signaling certainly have a role to play in fine-tuning the MAPK signaling cascades within ER stress response signaling.

There has been little research on the connections between DUSPs and ER stress in neurodegenerative disease, making it a fresh field to explore. The localization of DUSPs around the ER is likely a deciding factor in whether they participate in ER stress response. However, a few reports do offer flickering insights into the role of DUSPs in this context. DUSP1 has a role in activating BCL2 and caspases, and decreasing the neuroprotective protein CEBP/β during ischemic injury \[[@B129-ijms-18-01963]\]. Further, one study has shown that inactive PERK may indirectly affect the nuclear transportation of PTEN and sequester it to the cytoplasm \[[@B130-ijms-18-01963]\]. Since the consequence of activating PTEN is known to be the inactivation of PI3K/AKT signaling, under ER stress conditions, AKT activation may be expected to be reduced. However, given the ambiguous role of PTEN in neurodegeneration, we suspect the consequences of PERK inhibition on PTEN/PI3K/AKT axis could be complex and either result in protection or toxicity depending on the proteopathy model being studied.

6.2. Autophagy {#sec6dot2-ijms-18-01963}
--------------

Autophagy is another well-known process that participates in cellular stress responses to affect proteostasis. The general mechanism involves (i) the initiation of autophagy at phagophore assembly site (PAS); (ii) nucleation of the phagophore membrane that engulfs misfolded proteins and damaged organelles; (iii) membrane elongation leading to the genesis of an autophagosome and (iv) fusion with a lysosome to form an autophagolysosome structure, which degrades the engulfed contents and allows them to be recycled. Several proteins are well-known primary contributors to autophagic progression, including (a) mTORC1 dependent--ULK complex and mTORC1-independent AKT and EGFR signaling during the formation of PAS; (b) the Beclin1--Vps34 complex during nucleation; (c) ATG12--ATG5--ATG16L and LC3--phosphatidylethanolamine (PE) complexes, which contribute to phagophore expansion; (d) autophagy receptors and adaptor proteins that tether target proteins to be degraded and (e) mTORC1, which helps in terminating autophagy \[[@B131-ijms-18-01963],[@B132-ijms-18-01963]\].

Because the MAPK pathways can crosstalk with autophagy pathways, MAPKs are important regulators that may influence the outcome of the autophagic progression. For example, ERK signaling can activate autophagy in neurons in response to neurotoxins and has been associated with non-apoptotic neuronal death which is suspected to be autophagic in nature \[[@B133-ijms-18-01963]\]. JNK signaling also activates autophagy by regulating the transcription of *Atg* genes, and phosphorylates BCL-2, causing its dissociation from Beclin1 to promote autophagy \[[@B134-ijms-18-01963]\]. p38 signaling, on the other hand, has a cell-type dependent effect on activation and inhibition of autophagy \[[@B135-ijms-18-01963]\]. Autophagy modulation or dysfunction has been noted in several neurodegenerative diseases, including AD, PD, HD, ALS, and DUSP EPM2A-induced Lafora disease \[[@B136-ijms-18-01963]\].

DUSP1 provides an illustrative example of the effects of phosphatase mediated regulation of autophagy. Knockdown of *DUSP1* leads to induction of autophagy in ERK-dependent manner as observed in ovarian cancer cells. *DUSP1* knockdown probably mediates this effect via reduced dephosphorylation of ULK and increased LC3II formation which then results in autophagosome formation and maturation \[[@B137-ijms-18-01963]\]. DUSP1 may also dephosphorylate the scaffolding protein, JIP1, to maintain retrograde transport of autophagosomes in axons, thus allowing them to mature and help in protein clearance \[[@B138-ijms-18-01963]\]. In addition to DUSP1, the yeast homolog of DUSP12, YVH1, was shown to aid in the formation of the PAS structure after TORC1 inactivation which triggers the initiation of autophagy \[[@B139-ijms-18-01963]\]. In another instance, PTEN phosphorylation and nuclear translocation led to the induction of autophagy in cancer cell lines that experienced topotecan-induced DNA damage \[[@B140-ijms-18-01963]\]. Moreover, Laforin also positively increased autophagy by increasing the levels of LC3II \[[@B141-ijms-18-01963]\].

6.3. Apoptosis {#sec6dot3-ijms-18-01963}
--------------

Apoptosis is the process of programmed cell death, in which caspases are activated through either the extrinsic or intrinsic activation pathways. The extrinsic pathway is initiated by the binding of death receptors to their ligands, which then activates caspase 8 and finally, the downstream effector caspases---caspase-3 and caspase-7. The intrinsic pathway is triggered by intracellular stimuli such as DNA damage or ER stress, which induce mitochondrial outer membrane permeability (MOMP) and the release of cytochrome C to the cytosol. Once in the cytosol, cytochrome c activates the apoptosome, including caspase-9, and then subsequently activates effector caspase-3 and caspase-7. Ultimately, effector caspase activation is irreversible and leads to cell death \[[@B142-ijms-18-01963],[@B143-ijms-18-01963]\]. The MAPK signaling pathways have been implicated in mediating signals that initiate apoptosis in various neurodegenerative diseases, such as AD, PD and ALS \[[@B143-ijms-18-01963],[@B144-ijms-18-01963]\]. Naturally, some DUSPs have been shown to be involved in regulating the MAPK proteins to influence apoptosis. As an example, DUSP1 can dephosphorylate JNK proteins and hence play a role in downregulating apoptosis upon growth factor withdrawal in cervical ganglion neurons \[[@B145-ijms-18-01963]\]. DUSP13a, on the other hand, can induce apoptosis through ASK1/caspase-3 or casapase-9 signaling axis \[[@B45-ijms-18-01963]\]. Meanwhile, STYXL1 is a mitochondrial phosphatase that opposes activation of the intrinsic apoptotic pathway by modulating MOMP and may have potential to enhance cell survival \[[@B146-ijms-18-01963]\].

Thus, we find that various DUSPs play disparate roles in regulating the ER stress response, autophagy and apoptosis. However, it remains to be investigated if other members of the DUSP family have any potential roles in these branches of proteostasis.

7. Discussion {#sec7-ijms-18-01963}
=============

As critical regulators of dephosphorylation, DUSPs are recognized to be centrally involved in a variety of cellular and biochemical processes. They are commonly encountered points of control for MAPK signaling in numerous biomedical contexts. Emerging reports of DUSP involvement in other crucial signaling pathways, such as PI3/AKT or STAT signaling, corroborates their importance in the cell. This protein family is well-known to be involved in many cellular functions such as cell cycle regulation, proliferation, and differentiation. Moreover, some DUSPs can also function as scaffolding proteins, mRNA capping enzymes and glucan-binding moieties \[[@B71-ijms-18-01963]\]. Interestingly, previous work has also demonstrated the involvement of DUSPs in tissue or organism-wide responses, such as immune response and tumor suppression \[[@B78-ijms-18-01963]\]. Moreover, the subcellular or tissue specific localization of a DUSP may have influences on its activity. With so much diversity in functional targets, it is clear that DUSPs are important components of the cellular machinery.

The involvement of DUSPs in distinct individual pathways of neuronal proteostasis have been described and presented herein, however, an integrated view of how DUSPs orchestrate multiple proteostasis pathways is still emerging. In this review, we have summarized the known roles of DUSPs that may influence progression of protein aggregation diseases. In this context, regulation of cell signaling-mediated phosphorylation events may modulate proteotoxicity by influencing a variety of proteostatic processes. Two of the most important defensive processes in neurodegenerative disease are the stress responses to heat shock and the oxidative stress, and accumulating evidence shows that DUSPs are centrally involved in regulating these responses. In addition, we describe the initial findings with regards to DUSP-mediated regulation of ER stress, autophagy, and apoptosis. An illustrated working model recounts the involvement of DUSPs in neuronal proteostasis as shown in [Figure 3](#ijms-18-01963-f003){ref-type="fig"}.

Based on the widespread regulatory activities of DUSPs it may be prudent to consider them as potential therapeutic targets for neurodegenerative diseases. DUSPs exhibit high diversity in their downstream targets, which is an important consideration that may be exploited in the development of therapeutic strategies. DUSPs all bear a protein-tyrosine phosphatase (PTP) domain, however, the active site pocket of DUSPs is shallower than most PTPs \[[@B14-ijms-18-01963]\]. This allows for some level of promiscuity in target recognition and perhaps can provide a reason for their dual-specificity towards phospho-Ser/Thr and phospho-Tyr. Moreover, several DUSPs have their own characteristic domains or motifs, such as the SH2 domain or PTB/PI domain ([Table 1](#ijms-18-01963-t001){ref-type="table"}), which can also be considered as sites to potentially modulate DUSP activity. We provide an exhaustive list of inhibitors and activators of DUSPs which have been validated in previous literature in [Table 2](#ijms-18-01963-t002){ref-type="table"}. Several of these chemical compounds are already available as commercial pharmacological drugs, whereas others are merely non-specific inhibitors of phosphatase activity. Indeed, sodium orthovanadate is a classical phosphatase activity inhibitor and can inhibit most DUSP phosphatase activities \[[@B147-ijms-18-01963]\]. To our knowledge, there are only a few DUSP activators that are known. Besides small molecule inhibitors and activators, DUSP modulation may be achieved by physiological means, including transcription, epigenetic or post-translational modifications, subcellular localization, and manipulation of DUSP catalytic activities of DUSPs by upstream modulators.

Rightfully, DUSP manipulation has been suggested as a therapeutic strategy in several diseases apart from neurodegeneration such as in cancer, arthritis, diabetes, ischemia/neuronal injury, and cardiomyopathy among others \[[@B148-ijms-18-01963]\]. In addition, there are several reports indicating the possible association of DUSPs with neurological conditions other than those mentioned in this article. For instance, the individual association of DUSP2, DUSP 4, DUSP 6, DUSP 8, DUSP 11, DUSP 13, DUSP 24 has been reported with ataxin-1, which is the causative protein of spinocerebellar ataxia type 1 \[[@B149-ijms-18-01963]\]. The splicing abnormalities of DUSP22 were shown to occur in spinal muscular atrophy motor neurons \[[@B150-ijms-18-01963]\]. *STYXL1* has recently been suggested as a candidate gene involved in intellectual disability and seizures \[[@B151-ijms-18-01963]\]. A few DUSPs appeared to be dysregulated in major depressive disorder by microarray analysis, wherein, the pathogenic role of DUSP1 in depression was further confirmed \[[@B48-ijms-18-01963]\]. Finally, given that the pathological core of prion protein (PrP27--30) contains cofilin and Hsp90 \[[@B152-ijms-18-01963]\], it is plausible that DUSP mediated regulation of cofilin, and potentially Hsp90, could contribute to the modulation of the pathogenesis of prion diseases. Therefore, DUSP manipulation could also offer therapeutic avenues in the aforementioned diseases.

The Clinical Trials website (<https://clinicaltrials.gov/>) as on 30 August 2017, lists trials for (a) the changes in DUSP1 expression in response to treatment for depression; (b) cross-sectional and longitudinal study of individuals with autism and germline heterozygous *PTEN* mutations; (c) everolimus drug and neurocognition in PTEN hamartoma tumor syndrome; and (d) DUSP6 expression changes as biomarker in response to non-small cell lung cancer, thyroid cancer, and advanced solid tumor treatments. Furthermore, there are a few compounds currently under investigation in clinical trials that are also DUSP-manipulating compounds, including magnesium chloride, arsenite, pentamidine, and PTP inhibitors. Those compounds are tested for their efficacy in various clinical conditions, such as cancer, arthritis, muscular dystrophy, seizures, depression, diabetic neuropathy, neuropathic pain, and infertility. It is worth noting that only DUSP23 and PTEN targeting drugs are listed under experimental status on the DrugBank online resource \[[@B153-ijms-18-01963]\].

Mouse models carrying targeted manipulation of individual *DUSP* genes have been reported in literature. These in vivo models of DUSPs could be utilized for experimental works addressing how each DUSP members may play a role in the modulation of neuronal proteostasis as well as neurodegeneration. We provide a list of reported mouse models previously employed in biomedical studies in [Table 2](#ijms-18-01963-t002){ref-type="table"}. Comprehensive information on transgenic or mutated strains is readily accessible from online resources, such as the Jackson Laboratory (<https://www.jax.org/>), the Knockout Mouse Project (KOMP; <https://www.komp.org/>), the Mutant Mouse Resource and Research Centers (MMRRC; <https://www.mmrrc.org/>), and the International Mouse Strain Resource (IMSR, <http://www.findmice.org/>). Additional modes of DUSP manipulation could include immunotherapies, gene therapies, and blood-based therapies. Currently, there is information available only with immunotherapies for PTP4A subfamily and gene therapy for PTEN in cancer treatments \[[@B148-ijms-18-01963],[@B154-ijms-18-01963]\]. The potential advantages of modulating DUSPs may be evaluated in a case-by-case basis given the diversity of their subsequent downstream targets. Conditional manipulations of *DUSP* genes, instead of systemic manipulations, could be predicted to have a safer outcome and avoid potential embryonic lethality due to *DUSP* full knockout \[[@B155-ijms-18-01963]\]. Together, these genetic tools will enable us to mechanistically address the critical roles of DUSPs in neuronal proteostasis.

8. Conclusions {#sec8-ijms-18-01963}
==============

With the present and emerging data, it is becoming more apparent that DUSPs are essential manipulators of neurotoxicity and neuronal proteostasis. We hope this review succeeds in providing a baseline upon which new studies can be founded.
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6-OHDA

6-Hydroxydopamine

AD

Alzheimer's disease

ADF

Actin depolymerizing factor

ALS

Amyotrophic lateral sclerosis

ASK1

Apoptosis signal-regulating kinase 1

ATF

Activating transcription factor

ATG

Autophagy related

BCL

B-cell lymphoma

BIM

BCL-2 interacting mediator of cell death

CDC14

Cell division cycle 14

CDK

Cyclin-dependent kinase

CEBP/β

CCAAT/enhancer-binding protein β

CHOP

C/EBP homologous protein

DUSP

Dual-specificity phosphatase

eIF2α

Eukaryotic Initiation Factor 2 α

EGFR

Epidermal growth factor receptor

EPM2A

Epilepsy, Progressive Myoclonus type 2A (the gene encodes Laforin)

ERK

Extracellular signal--regulated kinase

HD

Huntington's disease

HSF

Heat shock factor

Hsp

Heat shock protein

HSR

Heat shock response

IP3R

Inositol trisphosphate receptor

IRE1α

Inositol-requiring enzyme 1

JIP

JNK-interacting protein-1

JNK

c-Jun N-terminal kinase

LC3

Microtubule-associated protein 1A/1B-light chain 3

LIMK

Lin11, Isl-1 and Mec-3 domain kinase

MAPK

Mitogen-activated protein kinase

MK-2

MAPK-activated protein kinase 2

MKP

MAPK phosphatase

MOMP

Mitochondrial outer membrane permeabilization

mTORC1

Mammalian target of rapamycin complex 1

OxR

Oxidative stress

PD

Parkinson's disease

PERK

Protein kinase RNA-like endoplasmic reticulum kinase

PI(5)P

Phosphatidylinositol 5-phosphate

PI3K/AKT

Phosphoinositide 3-kinase/Protein kinase B

PIP3

Phosphatidylinositol 3,4,5 trisphosphate

PN

Proteostasis network

PP2B

Protein phosphatase 2B

PTEN

Phosphatase and tensin homolog

PTP

Protein tyrosine phosphatase

PUMA

p53 Upregulated modulator of apoptosis

ROS

Reactive oxygen species

RYR

Ryanodine receptor

SSH

Slingshot protein phosphatase

STAT

Signal transducer and activator of transcription

STEP

Striatal-enriched protein tyrosine phosphatase

STYX(L1)

Serine/threonine/tyrosine-interacting-like protein

ULK

Unc-51 like autophagy activating kinase

VH1

Vaccinia virus H1 phosphatase
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###### 

List of the Alternative Names of Dual Specificity Phosphatase (DUSP) Family Members.

  No.   Gene Name   Entrez Gene ID \*   UniProtKB ^§^   Alternative Name (s) \*
  ----- ----------- ------------------- --------------- ------------------------------------------------------------------------------
  1     *DUSP1*     1843                P28562          HVH1; MKP1; CL100; MKP-1; PTPN10
  2     *DUSP2*     1844                Q05923          PAC-1
  3     *DUSP4*     1846                Q13115          TYP; HVH2; MKP2; MKP-2
  4     *DUSP5*     1847                Q16690          DUSP; HVH3
  5     *DUSP6*     1848                Q16828          HH19; MKP3; PYST1
  6     *DUSP7*     1849                Q16829          MKPX; PYST2
  7     *DUSP8*     1850                Q13202          HB5; HVH8; HVH-5; C11orf81
  8     *DUSP9*     1852                Q99956          MKP4; MKP-4
  9     *DUSP10*    11221               Q9Y6W6          MKP5; MKP-5
  10    *DUSP16*    80824               Q9BY84          MKP7; MKP-7
  11    *STYXL1*    51657               Q9Y6J8          DUSP24; MKSTYX; MK-STYX
  12    *DUPD1*     338599              Q68J44          FMDSP; DUSP27
  13    *DUSP3*     1845                P51452          VHR
  14    *DUSP11*    8446                O75319          PIR1
  15    *DUSP12*    11266               Q9UNI6          YVH1; DUSP1
  16    *DUSP13*    51207               Q9UII6          BEDP; MDSP; TMDP; SKRP4; DUSP13A; DUSP13B
  17    *DUSP14*    11072               O95147          MKP6; MKP-L
  18    *DUSP15*    128853              Q9H1R2          VHY; C20orf57
  19    *DUSP18*    150290              Q8NEJ0          DSP18; DUSP20; LMWDSP20
  20    *DUSP19*    142679              Q8WTR2          SKRP1; DUSP17; LMWDSP3; TS-DSP1
  21    *DUSP21*    63904               Q9H596          LMWDSP21
  22    *DUSP22*    56940               Q9NRW4          VHX; JKAP; JSP1; MKPX; JSP-1; MKP-x; LMWDSP2; LMW-DSP2
  23    *DUSP23*    54935               Q9BVJ7          VHZ; MOSP; LDP-3; DUSP25
  24    *DUSP26*    78986               Q9BV47          MKP8; NEAP; DSP-4; LDP-4; MKP-8; NATA1; SKRP3; DUSP24
  25    *DUSP28*    285193              Q4G0W2          VHP; DUSP26
  26    *EPM2A*     7957                O95278          EPM2; MELF
  27    *PTPMT1*    114971              Q8WUK0          PLIP; 1110001D10Rik; 2810004N20Rik
  28    *RNGTT*     8732                O60942          HCE; HCE1; hCAP; CAP1A
  29    *STYX*      6815                Q8WUJ0          STYX
  30    *SSH1*      54434               Q8WYL5          SSH1L
  31    *SSH2*      85464               Q76I76          SSH-2; SSH-2L
  32    *SSH3*      54961               Q8TE77          SSH3L
  33    *PTP4A1*    7803                Q93096          HH72; PRL1; PRL-1; PTPCAAX1; PTP(CAAX1)
  34    *PTP4A2*    8073                Q12974          HH13; OV-1; PRL2; HH7-2; PRL-2; PTP4A; HU-PP-1; PTPCAAX2; ptp-IV1a; ptp-IV1b
  35    *PTP4A3*    11156               O75365          PRL3; PRL-3; PRL-R
  36    *CDC14A*    8556                Q9UNH5          cdc14; hCDC14; DFNB105
  37    *CDC14B*    8555                O60729          CDC14B3; Cdc14B1; Cdc14B2; hCDC14B
  38    *CDKN3*     1033                Q16667          KAP; CDI1; CIP2; KAP1
  39    *PTPDC1*    138639              A2A3K4          Naa-1; Ptpcd1; AI843923; AW456874
  40    *PTEN*      5728                P60484          BZS; DEC; CWS1; GLM2; MHAM; TEP1; MMAC1; PTEN1; 10q23del; PTEN β
  41    *TNS1*      7145                Q9HBL0          TNS; MXRA6; MST091; MST122; MST127; MSTP091; MSTP122; MSTP127; PPP1R155
  42    *TNS2*      23371               Q63HR2          C1TEN; TENC1; C1-TEN
  43    *TPTE*      7179                P56180          CT44; PTEN2
  44    *TPTE2*     93492               Q6XPS3          TPIP

\* Data obtained from Gene (Internet). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information (NCBI); 2004---\[20170806\]. Available from: <https://www.ncbi.nlm.nih.gov/gene/> \[[@B237-ijms-18-01963]\]; ^§^ Data obtained from UniProt \[[@B28-ijms-18-01963]\], <http://www.uniprot.org/>.

![The schematic classifications of human dual-specificity phosphatases. Phosphatases are classified into seven gene families, of which Protein Phosphatases are one. They are further categorized into five groups, which includes Class I classical Cys-based Phosphatases. This group is then subdivided into dual-specificity phosphatases, Receptor-type Protein Tyrosine Phosphatases, and Non-receptor-type Protein Tyrosine Phosphatases. Dual-specificity Phosphatases are categorized by six subfamilies: (i) Mitogen-activated Protein Kinase Phosphatases (MKP); (ii) Atypical DUSPs; (iii) Slingshot Protein Phosphatases; (iv) Protein Tyrosine Phosphatases type IVA; (v) CDC14 Phosphatases and (vi) PTEN Protein Phosphatases. Members of each subfamily are as listed in the figure. Data are adapted from the HUGO Gene Nomenclature Committee at the European Bioinformatics Institute, <http://www.genenames.org/>.](ijms-18-01963-g001){#ijms-18-01963-f001}

###### 

Structural features of typical members from each DUSP subfamily. (**a**--**f**) Molecular representations of typical member from each DUSP subfamily using data available from Protein Data Bank (PDB) and redrawn using Avogadro: an open-source molecular builder and visualization tool, version 1.XX, <http://avogadro.cc/>. Cyan color on the structure indicates helix, yellow color indicates sheet, and brown color represents loop structures; (**a**) Image of 1M3G represents DUSP2 structure \[[@B20-ijms-18-01963]\] of the MKP subfamily; (**b**) Image of 3F81 represents DUSP3 structure \[[@B21-ijms-18-01963]\] of the atypical-DUSP subfamily; (**c**) Image of 2NT2 represents SSH2 structure \[[@B22-ijms-18-01963]\] of the slingshot phosphatase subfamily; (**d**) Image of 1XM2 represents PTP4A1 structure \[[@B23-ijms-18-01963]\] of the PTP4A phosphatase subfamily; (**e**) Image of 1OHC represents CDC14A structure \[[@B24-ijms-18-01963]\] of the CDC14 phosphatase subfamily; (**f**) Image of 1D5R represents PTEN structure \[[@B25-ijms-18-01963]\] of the PTEN phosphatase subfamily; (**g**) Domain representation of typical member of each DUSP subfamily: DUSP2, DUSP3, SSH2, PTP4A1, CDC14A and PTEN created from data available on InterPro \[[@B26-ijms-18-01963]\] (not drawn-to-scale). Abbreviations of domains listed in the figure include, PTP-like: Protein tyrosine phosphatase-like; DSPc: Dual-specificity phosphatase, catalytic; DSP-N: Dual-specificity phosphatase, N-terminal. Numbers on the right side indicate amino acid length. It should be noted that variations exist in individual members from each subfamily in presence/absence of protein domains and taken into consideration. For further information on protein domains of an individual DUSP, please refer to [Table 1](#ijms-18-01963-t001){ref-type="table"} and \[[@B27-ijms-18-01963]\]; (**h**) Multiple sequence alignment of typical members of each DUSP subfamily: DUSP2, DUSP3, SSH2, PTP4A1, CDC14A and PTEN. Amino acid sequences were obtained from UniProt \[[@B28-ijms-18-01963]\], and aligned using Clustal Omega at EMBL-EBI \[[@B29-ijms-18-01963],[@B30-ijms-18-01963]\]. Blue box indicates the conserved catalytic DUSP motif (V)-HC-XX-X-XX-R-(S/T), where X represents any amino acid; (:) indicates conservation between groups of strongly similar properties; (\*) indicates a conserved residue; (.) indicates conservation between groups of weakly similar properties.

![](ijms-18-01963-g002a)

![](ijms-18-01963-g002b)

![A proposed working model showing the involvement of DUSPs in pathways of proteostasis that contribute to neurodegeneration. A simplified version of proteostasis is represented under three central themes---protein biogenesis, protein quality control processes, and protein degradation. In this article, we highlight the role of DUSPs in protein quality control and breakdown, with respect to neurological disorders. Protein translation, folding, and transport occur largely within the endoplasmic reticulum (ER). An increased load of misfolded proteins in the ER evokes the ER stress response, and several DUSPs have been shown to participate in this pathway of proteostasis. Next, protein aggregates are the by-products of accumulated misfolded proteins and represent the hallmarks of many neurodegenerative diseases. DUSPs participate in phosphorylation-dependent modulation of protein aggregation mostly by regulating MAPK and related signaling pathways. Reactive oxygen species (ROS) production is often triggered in response to protein aggregates and results in oxidative stress. DUSPs participate in the oxidative stress response (OxR), and may have protective or aggravating roles, depending on the phosphatase. Further, DUSPs have a confirmed involvement in the heat shock response (HSR) pathway by either self-modulation or by direct interaction with the heat shock proteins/molecular chaperones. Heat shock proteins assist misfolded and aggregated proteins to refold and attain their native conformation. Proteins which fail to refold even after assistance from the heat shock response pathway, may then be degraded (indicated by dotted arrow). Finally, autophagy is the major degradation route for toxic-protein aggregates, and is known to be influenced by some DUSPs. When individual cells become overwhelmed by proteotoxic stress, they may enter apoptosis. The initiation of the apoptotic cascade is also known to be influenced by certain DUSPs.](ijms-18-01963-g003){#ijms-18-01963-f003}
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###### 

The Correlation between Dysfunctional DUSP Members with Neural Abnormalities.

  No.   Gene Name   Family & Domains      Possible Association with Neurological Deficits or Affected Neuronal Functions   Gene Expression in Indicative Brain Regions
  ----- ----------- --------------------- -------------------------------------------------------------------------------- --------------------------------------------------
  1     *DUSP1*     a, b, c, d, e, Δ      HD \[[@B19-ijms-18-01963]\]                                                      CCx ^x^, CbCx ^x^, H ^x^, A ^y^, Sn ^y^
  2     *DUSP2*     a, b, c, d, Δ         Seizure \[[@B31-ijms-18-01963]\]                                                 CCx ^x^, CbCx ^y^, H ^y^, A ^y^, Sn ^y^
  3     *DUSP4*     a, b, c, d, Δ         Hippocampal synaptic function \[[@B32-ijms-18-01963]\]                           CCx ^y^, CbCx ^y^, H ^y^, A ^y^
  4     *DUSP5*     a, b, c, d, Δ         Cerebral ischemia \[[@B33-ijms-18-01963]\]                                       CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  5     *DUSP6*     a, b, c, d, Δ         Glutamate-induced cytotoxicity \[[@B34-ijms-18-01963]\]                          CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  6     *DUSP7*     a, b, c, d, Δ         ALS \[[@B35-ijms-18-01963]\]                                                     CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  7     *DUSP8*     a, b, c, d, Δ         Cerebral ischemia \[[@B36-ijms-18-01963]\]                                       CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  8     *DUSP9*     a, b, c, d, Δ         Neural fate commitment \[[@B37-ijms-18-01963]\]                                  H ^y^, A ^y^, NAc ^y^
  9     *DUSP10*    a, b, c, d, e, Δ      Oligodendrocyte differentiation \[[@B38-ijms-18-01963]\]                         CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  10    *DUSP16*    a, b, c, d, Δ         Axonal degeneration \[[@B39-ijms-18-01963]\]                                     CCx ^x^, CbCx ^x^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  11    *STYXL1*    a, b, d, Δ            Neuronal differentiation \[[@B40-ijms-18-01963]\]                                CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  12    *DUPD1*     a, b, e, Δ            Skeletal muscle atrophy \[[@B41-ijms-18-01963]\]                                 CCx ^x^, CbCx ^x^, H ^x^
  13    *DUSP3*     a, b, e, Δ            Glutamate-induced cytotoxicity \[[@B42-ijms-18-01963]\]                          CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  14    *DUSP11*    a, b, Δ               Seizure \[[@B43-ijms-18-01963]\]                                                 CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  15    *DUSP12*    a, b, f, Δ            Neuroblastoma GWAS \[[@B44-ijms-18-01963]\]                                      CCx ^x^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  16    *DUSP13*    a, b, e, Δ            Neuron development \[[@B45-ijms-18-01963]\]                                      Some regions of CCx ^z^
  17    *DUSP14*    a, b, e, Δ            HD \[[@B19-ijms-18-01963]\]                                                      CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  18    *DUSP15*    a, b, e, g, Δ         Oligodendrocyte differentiation \[[@B46-ijms-18-01963]\]                         Low expression
  19    *DUSP18*    a, b, e, Δ            SCI \[[@B47-ijms-18-01963]\]                                                     CCx ^x^, CbCx ^x^, H ^x^
  20    *DUSP19*    a, b, e, Δ            Depression \[[@B48-ijms-18-01963]\]                                              CCx ^x^
  21    *DUSP21*    a, b, e, Δ            Not defined                                                                      Not defined
  22    *DUSP22*    a, b, e, Δ            AD \[[@B49-ijms-18-01963]\]                                                      CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  23    *DUSP23*    a, b, Δ               Neuronal differentiation \[[@B50-ijms-18-01963]\]                                CCx ^x^, CbCx ^y^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  24    *DUSP26*    a, b, e, Δ            AD \[[@B6-ijms-18-01963]\]                                                       CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  25    *DUSP28*    a, b, Δ               Not defined                                                                      Low expression
  26    *EPM2A*     a, b, h, i, j, Δ      Lafora disease \[[@B51-ijms-18-01963]\]                                          CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  27    *PTPMT1*    a, b, Δ               AD GWAS \[[@B52-ijms-18-01963]\]                                                 CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  28    *RNGTT*     a, b, k, l, Δ         ASD RNA-Seq \[[@B53-ijms-18-01963]\]                                             CCx ^x^, CbCx ^y^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  29    *STYX*      a, b, Δ               Golgi fragmentation \[[@B54-ijms-18-01963]\]                                     CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  30    *SSH1*      a, b, m, o, Δ         Synaptic plasticity \[[@B55-ijms-18-01963]\]                                     CCx ^x^, CbCx ^y^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  31    *SSH2*      a, b, n, o, Δ         Neurite extension \[[@B56-ijms-18-01963]\]                                       CCx ^x^, CbCx ^y^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  32    *SSH3*      a, b, n, o, Δ         Actin reorganization \[[@B57-ijms-18-01963]\]                                    CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  33    *PTP4A1*    a, b, Δ               Cerebral ischemia \[[@B58-ijms-18-01963]\]                                       CCx ^y^, CbCx ^y^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  34    *PTP4A2*    a                     NCL \[[@B59-ijms-18-01963]\]                                                     CCx ^y^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  35    *PTP4A3*    a, b, Δ               MDD, Stress \[[@B60-ijms-18-01963]\]                                             CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  36    *CDC14A*    a, b, Δ               Diabetic stroke \[[@B61-ijms-18-01963]\]                                         CCx ^x^, CbCx ^x^, H ^x^, A ^y^
  37    *CDC14B*    a, b, Δ               Addictive behavior \[[@B62-ijms-18-01963]\]                                      CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NA ^y^
  38    *CDKN3*     a, p                  Neuroblastoma \[[@B63-ijms-18-01963]\]                                           Low expression
  39    *PTPDC1*    a, b, Δ               PD GWAS \[[@B64-ijms-18-01963]\]                                                 CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  40    *PTEN*      a, q, r, s, Δ         PD \[[@B65-ijms-18-01963]\]                                                      CCx ^x^, CbCx ^x^, H ^x^, A ^y^, SN ^y^, NAc ^y^
  41    *TNS1*      a, r, s, t, u, v      Not defined                                                                      CCx ^x^, CbCx ^x^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  42    *TNS2*      a, r, s, t, u, v, w   Schizophrenia \[[@B66-ijms-18-01963]\]                                           CCx ^y^, CbCx ^y^, H ^y^, A ^y^, SN ^y^, NAc ^y^
  43    *TPTE*      a, r, s, Δ            Neuropathic pain \[[@B67-ijms-18-01963]\]                                        Not defined
  44    *TPTE2*     a, r, s, Δ            Not defined                                                                      Not defined

a: PTP-like; b: DUSP family; c: MKP subfamily; d: Rhodanese-like; e: Atypical DUSP subfamily; f: Zinc finger C2H2-type; g: SMAD/FHA; h: Immunoglobulin-like; i: Carbohydrate-binding; j: Laforin; k: mRNA capping enzyme; l: Nucleic-acid binding, OB fold; m: Protein phosphatase Slingshot Homolog 1; n: Protein phosphatase Slingshot; o: DEK, C-terminal; p: CDKN3; q: DUSP-PTEN; r: Tensin-type phosphatase; s: C2; t: SH2; u: PH domain-like; v: PTB/PI domain; w: Protein Kinase C-like/PE/DAG-binding; Δ: Dual-specificity phosphatase, catalytic domain; AD: Alzheimer's disease; ALS: Amyotrophic lateral Sclerosis; ASD: Autism spectrum disorders; HD: Huntington's disease; MDD: Major depressive disorder; NCL: Neuronal ceroid lipofuscinosis; PD: Parkinson's disease; SCI: Spinal Cord Injury; GWAS: Genome-wide Association Studies; CCx: Cerebral cortex; CbCx: Cerebellar cortex; H: Hippocampus; A: Amygdala; SN: Substantia nigra; NAc: Nucleus accumbens; ^x^: Protein expression (data derived from the Human Protein Atlas \[[@B68-ijms-18-01963]\], <http://www.proteinatlas.org/>); ^y^: RNA-seq data of Genotype-Tissue expression (GTEx) project (derived from the Expression Atlas at EMBL-EBI, \[[@B69-ijms-18-01963]\], <https://www.ebi.ac.uk/>); ^z^: Microarray expression (derived from the © 2010 Allen Institute for Brain Science. Allen Human Brain Atlas. Available from: human.brain-map.org \[[@B70-ijms-18-01963]\]).
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###### 

Modulation of Dual-Specificity Phosphatase by various modes.

  S.No.   Gene Name   Inhibitors Validated in Biomedical Literature                                                                                                                                                                                                              Activators Validated in Biomedical Literature                                                                                                                           Mouse Model Employed in Biomedical Literature \*
  ------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  1       *DUSP1*     BCI ^Φ^ \[[@B156-ijms-18-01963]\], NSC 95397 ^Φ^ \[[@B157-ijms-18-01963]\], NU-126 \[[@B158-ijms-18-01963]\], Sanguinarine chloride ^Φ^ \[[@B159-ijms-18-01963]\]                                                                                          Salbutamol ^Φ^ \[[@B160-ijms-18-01963]\], Formoretol ^Φ^ \[[@B160-ijms-18-01963]\], Dexamethasone ^Φ^ \[[@B161-ijms-18-01963]\], JWH015 ^Φ^ \[[@B162-ijms-18-01963]\]   KO; Neuronal death \[[@B145-ijms-18-01963]\]
  2       *DUSP2*     Salubrinal ^Φ^ \[[@B163-ijms-18-01963]\]                                                                                                                                                                                                                   Not defined                                                                                                                                                             KO; Arthritis \[[@B164-ijms-18-01963]\]
  3       *DUSP4*     Y \[[@B165-ijms-18-01963]\]                                                                                                                                                                                                                                Not defined                                                                                                                                                             KO; Synaptic plasticity \[[@B32-ijms-18-01963]\]
  4       *DUSP5*     CSDDD2320, RR505, RR506, SM1842 \[[@B166-ijms-18-01963]\]                                                                                                                                                                                                  Not defined                                                                                                                                                             Transgenic; Inflammation \[[@B167-ijms-18-01963]\]
  5       *DUSP6*     BCI ^Φ^ \[[@B156-ijms-18-01963]\], NSC 95397 ^Φ^ \[[@B157-ijms-18-01963]\], NSC 45382 ^Φ^ \[[@B168-ijms-18-01963]\], NSC 295642 ^Φ^ \[[@B168-ijms-18-01963]\], NSC 357756 \[[@B168-ijms-18-01963]\]                                                        JWH015 ^Φ^ \[[@B162-ijms-18-01963]\]                                                                                                                                    KO; Allodynia \[[@B169-ijms-18-01963]\], Transgenic; FGFR signaling \[[@B170-ijms-18-01963]\]
  6       *DUSP7*     Y \[[@B171-ijms-18-01963]\]                                                                                                                                                                                                                                Not defined                                                                                                                                                             Not defined
  7       *DUSP8*     Arsenite ^Φ^, Anisomycin ^Φ^ inhibit the mouse ortholog M3/6 \[[@B172-ijms-18-01963]\]                                                                                                                                                                     Not defined                                                                                                                                                             KO, Transgenic; Ventricular remodeling \[[@B173-ijms-18-01963]\]
  8       *DUSP9*     Y \[[@B174-ijms-18-01963],[@B175-ijms-18-01963]\]                                                                                                                                                                                                          Not defined                                                                                                                                                             KO; Placental organogenesis \[[@B176-ijms-18-01963]\]
  9       *DUSP10*    AS077234-4 ^Φ^ \[[@B38-ijms-18-01963]\]                                                                                                                                                                                                                    Not defined                                                                                                                                                             KO; Immune response \[[@B177-ijms-18-01963]\]
  10      *DUSP16*    Y \[[@B178-ijms-18-01963]\]                                                                                                                                                                                                                                Not defined                                                                                                                                                             KO; Axon degeneration \[[@B39-ijms-18-01963]\]
  11      *STYXL1*    Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             Not defined
  12      *DUPD1*     NSC 95397 ^Φ^ \[[@B179-ijms-18-01963]\], NSC 663284 ^Φ^ \[[@B179-ijms-18-01963]\]                                                                                                                                                                          Not defined                                                                                                                                                             Not defined
  13      *DUSP3*     RK-682 ^Φ^ \[[@B180-ijms-18-01963]\], MLS-0437605 \[[@B181-ijms-18-01963]\], NU-126 \[[@B158-ijms-18-01963]\], Isovenaciolide \[[@B182-ijms-18-01963]\]                                                                                                    Not defined                                                                                                                                                             KO; Angiogenesis \[[@B183-ijms-18-01963]\]
  14      *DUSP11*    Sodium (ortho)vanadate ^Φ^ \[[@B184-ijms-18-01963]\], Magnesium Chloride ^Φ^ \[[@B184-ijms-18-01963]\]                                                                                                                                                     Not defined                                                                                                                                                             KO; Immune response \[[@B185-ijms-18-01963]\]
  15      *DUSP12*    Zinc chelators (*Possibly)* \[[@B186-ijms-18-01963]\]                                                                                                                                                                                                      Not defined                                                                                                                                                             KO; Cardiac hypertrophy \[[@B187-ijms-18-01963]\]
  16      *DUSP13*    PTP inhibitor V ^Φ^ \[[@B188-ijms-18-01963]\]                                                                                                                                                                                                              Not defined                                                                                                                                                             Not defined
  17      *DUSP14*    PTP inhibitor IV ^Φ^ \[[@B189-ijms-18-01963]\], NSC-95397 ^Φ^ \[[@B190-ijms-18-01963]\]                                                                                                                                                                    Not defined                                                                                                                                                             KO; Immune response \[[@B191-ijms-18-01963]\]
  18      *DUSP15*    Y \[[@B192-ijms-18-01963]\]                                                                                                                                                                                                                                Not defined                                                                                                                                                             Transgenic; Myelination \[[@B193-ijms-18-01963]\]
  19      *DUSP18*    Sodium orthovanadate ^Φ^ \[[@B194-ijms-18-01963]\], Iodoaretic acid ^Φ^ \[[@B195-ijms-18-01963]\]                                                                                                                                                          Not defined                                                                                                                                                             Not defined
  20      *DUSP19*    Sodium (ortho)vanadate ^Φ^ \[[@B196-ijms-18-01963]\]                                                                                                                                                                                                       Not defined                                                                                                                                                             Not defined
  21      *DUSP21*    Sodium orthovanadate ^Φ^ \[[@B194-ijms-18-01963]\]                                                                                                                                                                                                         Not defined                                                                                                                                                             Not defined
  22      *DUSP22*    Sodium (ortho)vanadate ^Φ^ \[[@B196-ijms-18-01963]\], BML-260 ^Φ^ \[[@B197-ijms-18-01963]\], PRL-3 Inhibitor 1 ^Φ^ \[[@B198-ijms-18-01963]\]                                                                                                               Not defined                                                                                                                                                             KO; Immune response \[[@B199-ijms-18-01963]\]
  23      *DUSP23*    Sodium orthovanadate ^Φ^ \[[@B200-ijms-18-01963]\], EDTA ^Φ^ \[[@B200-ijms-18-01963]\], *N*-ethylmaleimide ^Φ^ \[[@B200-ijms-18-01963]\], Y \[[@B201-ijms-18-01963]\]                                                                                      Not defined                                                                                                                                                             Not defined
  24      *DUSP26*    NSC-87877 ^Φ^ \[[@B202-ijms-18-01963]\], Ethyl-3,4-dephostatin ^Φ^ \[[@B203-ijms-18-01963]\], Y \[[@B204-ijms-18-01963]\]                                                                                                                                  Not defined                                                                                                                                                             Not defined
  25      *DUSP28*    U0216 ^Φ^ \[[@B205-ijms-18-01963]\]                                                                                                                                                                                                                        Not defined                                                                                                                                                             Not defined
  26      *EPM2A*     Nitric oxide ^Φ^ \[[@B206-ijms-18-01963]\], Glycogen ^Φ^ \[[@B207-ijms-18-01963]\], polysaccharides ^Φ^ \[[@B207-ijms-18-01963]\]                                                                                                                          Not defined                                                                                                                                                             KO; Lafora disease \[[@B208-ijms-18-01963]\]
  27      *PTPMT1*    Alexidine dihydrochloride ^Φ^ \[[@B209-ijms-18-01963]\], Y \[[@B210-ijms-18-01963]\]                                                                                                                                                                       Not defined                                                                                                                                                             KO; Cardiolipin biosynthesis \[[@B155-ijms-18-01963]\]
  28      *RNGTT*     Mizoribine Monophosphate ^Φ^ \[[@B211-ijms-18-01963]\]                                                                                                                                                                                                     Not defined                                                                                                                                                             Not defined
  29      *STYX*      Vandate (Sodium orthovanadate) ^Φ^ \[[@B212-ijms-18-01963]\]                                                                                                                                                                                               Not defined                                                                                                                                                             Not defined
  30      *SSH1*      Slingshot Inhibitor D3 ^Φ^ \[[@B213-ijms-18-01963]\], Sennoside A ^Φ^ \[[@B214-ijms-18-01963]\]                                                                                                                                                            Not defined                                                                                                                                                             Not defined
  31      *SSH2*      Slingshot Inhibitor D3 ^Φ^ \[[@B213-ijms-18-01963]\], Sennoside A ^Φ^ \[[@B214-ijms-18-01963]\], ZINC04307500 \[[@B215-ijms-18-01963]\]                                                                                                                    Not defined                                                                                                                                                             Not defined
  32      *SSH3*      Sennoside A ^Φ^ \[[@B214-ijms-18-01963]\]                                                                                                                                                                                                                  Not defined                                                                                                                                                             KO; Unknown \[[@B216-ijms-18-01963]\]
  33      *PTP4A1*    Thienopyridone ^Φ^ \[[@B217-ijms-18-01963]\], Analog 3 ^Φ^ \[[@B218-ijms-18-01963]\], Pentamidine ^Φ^ \[[@B219-ijms-18-01963]\]                                                                                                                            Not defined                                                                                                                                                             CKO; Liver regeneration \[[@B220-ijms-18-01963]\]
  34      *PTP4A2*    Thienopyridone ^Φ^ \[[@B217-ijms-18-01963]\], Analog 3 ^Φ^ \[[@B218-ijms-18-01963]\], Pentamidine ^Φ^ \[[@B219-ijms-18-01963]\]                                                                                                                            Not defined                                                                                                                                                             KO; Oncogenesis \[[@B221-ijms-18-01963]\]
  35      *PTP4A3*    BR-1 ^Φ^ \[[@B222-ijms-18-01963]\], Analog 13 \[[@B223-ijms-18-01963]\], PRL-3 inhibitor 1^Φ^ \[[@B224-ijms-18-01963]\], Thienopyridone ^Φ^ \[[@B217-ijms-18-01963]\], Analog 3 ^Φ^ \[[@B218-ijms-18-01963]\], Pentamidine ^Φ^ \[[@B219-ijms-18-01963]\]   Not defined                                                                                                                                                             KO; Colon cancer \[[@B225-ijms-18-01963]\]
  36      *CDC14A*    Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             Double KO; DDR \[[@B226-ijms-18-01963]\]
  37      *CDC14B*    Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             CKO; DDR \[[@B227-ijms-18-01963]\]
  38      *CDKN3*     Sodium orthovanadate ^Φ^ \[[@B228-ijms-18-01963]\]                                                                                                                                                                                                         Not defined                                                                                                                                                             KO; Cancer \[[@B229-ijms-18-01963]\]
  39      *PTPDC1*    Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             KO; Unknown \[[@B230-ijms-18-01963]\]
  40      *PTEN*      bpV(phen) ^Φ^ \[[@B231-ijms-18-01963]\], bpV(pic) ^Φ^ \[[@B231-ijms-18-01963]\], VO-Ohpic ^Φ^ \[[@B231-ijms-18-01963]\], SF1670 ^Φ^ \[[@B231-ijms-18-01963]\], bpV(HOpic) ^Φ^ \[[@B232-ijms-18-01963]\]                                                    Not defined                                                                                                                                                             KO; Cortical dysplasia \[[@B233-ijms-18-01963]\]
  41      *TNS1*      Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             KO; Angiogenesis \[[@B234-ijms-18-01963]\]
  42      *TNS2*      DHTS ^Φ^ \[[@B235-ijms-18-01963]\]                                                                                                                                                                                                                         Not defined                                                                                                                                                             KO; Renal failure \[[@B236-ijms-18-01963]\]
  43      *TPTE*      Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             Not defined
  44      *TPTE2*     Not defined                                                                                                                                                                                                                                                Not defined                                                                                                                                                             Not defined

^Φ^ Commercially available; Y: In silico predictions validated by enzyme assay; \* Disease phenotype studied is indicated (not necessarily neurological); KO: Knock-out; CKO: Conditional Knock-out; FGFR: Fibroblast-growth factor receptor; DDR: DNA-damage response.
